Acumen Pharmaceuticals (ABOS) Competitors $1.73 -0.04 (-2.26%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.77 +0.04 (+2.25%) As of 10/3/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. TVRD, IMRX, CTNM, ENGN, AMRN, TKNO, CAPR, REPL, CGC, and ALECShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Tvardi Therapeutics (TVRD), Immuneering (IMRX), Contineum Therapeutics (CTNM), enGene (ENGN), Amarin (AMRN), Alpha Teknova (TKNO), Capricor Therapeutics (CAPR), Replimune Group (REPL), Canopy Growth (CGC), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Tvardi Therapeutics Immuneering Contineum Therapeutics enGene Amarin Alpha Teknova Capricor Therapeutics Replimune Group Canopy Growth Alector Acumen Pharmaceuticals (NASDAQ:ABOS) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Do insiders and institutionals believe in ABOS or TVRD? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 9.3% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ABOS or TVRD? Acumen Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 304.62%. Tvardi Therapeutics has a consensus target price of $64.25, indicating a potential upside of 59.71%. Given Acumen Pharmaceuticals' higher probable upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Tvardi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has better valuation and earnings, ABOS or TVRD? Tvardi Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.76Tvardi Therapeutics$7.14M52.85-$70.87MN/AN/A Which has more risk & volatility, ABOS or TVRD? Acumen Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Is ABOS or TVRD more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -678.79%. Acumen Pharmaceuticals' return on equity of -81.39% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -81.39% -61.96% Tvardi Therapeutics -678.79%-565.83%-66.71% Does the media prefer ABOS or TVRD? In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 0.78 beat Tvardi Therapeutics' score of 0.67 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAcumen Pharmaceuticals beats Tvardi Therapeutics on 7 of the 10 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.79M$3.36B$6.14B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-0.7622.1485.3826.71Price / SalesN/A458.33605.26131.81Price / CashN/A47.8637.9061.31Price / Book0.579.9312.556.55Net Income-$102.33M-$52.80M$3.31B$277.50M7 Day Performance21.83%5.22%4.28%2.42%1 Month Performance20.14%10.61%6.90%8.63%1 Year Performance-27.00%25.03%70.54%31.60% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.2332 of 5 stars$1.73-2.3%$7.00+304.6%-27.0%$104.79MN/A-0.7620News CoverageTVRDTvardi Therapeutics3.3064 of 5 stars$36.90+1.6%$64.25+74.1%N/A$340.59M$7.14M0.0080News CoverageGap UpIMRXImmuneering3.9086 of 5 stars$6.75-16.5%$17.75+163.0%+144.9%$335.89MN/A-3.5760Analyst ForecastShort Interest ↑High Trading VolumeCTNMContineum Therapeutics2.9794 of 5 stars$11.82-0.8%$22.20+87.8%-33.2%$334.26M$50M-5.3731Positive NewsENGNenGene3.0424 of 5 stars$6.45-0.6%$19.50+202.3%+16.9%$332.23MN/A-3.3931Short Interest ↑AMRNAmarin0.6287 of 5 stars$16.08+0.5%$12.00-25.4%+55.5%$330.92M$228.61M-4.38360High Trading VolumeTKNOAlpha Teknova1.4955 of 5 stars$5.65-6.9%$10.00+77.0%+14.6%$324.84M$37.74M-13.45240CAPRCapricor Therapeutics2.5662 of 5 stars$7.41+4.5%$22.25+200.3%-66.0%$324.13M$22.27M-4.52101REPLReplimune Group4.7371 of 5 stars$4.34+5.1%$6.50+49.8%-59.1%$322.37MN/A-1.34210CGCCanopy Growth0.8549 of 5 stars$1.57+17.2%N/A-69.0%$321.40M$225.65M-0.523,150High Trading VolumeALECAlector3.6839 of 5 stars$3.05-1.6%$4.17+36.6%-28.1%$313.76M$100.56M-2.63270Analyst Revision Related Companies and Tools Related Companies TVRD Competitors IMRX Competitors CTNM Competitors ENGN Competitors AMRN Competitors TKNO Competitors CAPR Competitors REPL Competitors CGC Competitors ALEC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
